DelveInsight’s, “Bone Metastases Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Bone Metastasis Treatment Landscape. Click here to read more @ Bone Metastasis Pipeline Outlook

Key Takeaways from the Bone Metastasis Pipeline Report

• In June 2025, Shenyang Sunshine Pharmaceutical Co. Ltd announced a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer pain. The study includes two stages: a single-arm, open-label, dose-escalation and dose-expansion Phase Ib followed by a randomized, double-blind, placebo-controlled Phase IIa.
• DelveInsight’s Bone Metastasis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Bone Metastasis treatment.
• The leading Bone Metastasis Companies such as Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc., BiologicsMD, Luye Pharma Group Ltd., QSAM Biosciences Inc., Serene, LLC, Isotopen Technologien Munchens and others.
• Promising Bone Metastasis Pipeline Therapies such as Radium Ra 223 Dichloride, MW032, Xgeva, Zoledronic Acid, Radium-223 chloride (BAY88-8223), Pamidronate, Docetaxel and others.

Discover groundbreaking developments in Bone Metastasis Therapies! Gain in-depth knowledge of key Bone Metastasis clinical trials, emerging drugs, and market opportunities @ Bone Metastasis Clinical Trials Assessment

Bone Metastasis Emerging Drugs Profile

• MW032: Mabwell (Shanghai) Bioscience Co., Ltd.

MW032 is a Denosumab biosimilar being developed by Mabwell (Shanghai) Bioscience Co., Ltd. Denosumab is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFκB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. MW032 is currently in Phase III stage of development to treat Bone Metastases from Solid Tumors.

• ALMB-0168: AlaMab Therapeutics

ALMB-0168 is a first-inclass humanized monoclonal antibody agonist for hemichannel Cx43 membrane protein. Through the activation of Cx43 protein to release tumor-inhibiting cytokines, ALMB-0168 has shown to effectively inhibit osteosarcoma and bone metastasis in pre-clinical in vitro and in vivo animal studies. ALMB-0168 has received Orphan Disease Drug and Rare Pediatric Disease designations from the FDA for its use in osteosarcoma.

The Bone Metastasis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Bone Metastasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bone Metastasis Treatment.
• Bone Metastasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bone Metastasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bone Metastasis market

Stay informed about the Bone Metastasis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Bone Metastasis Unmet Needs

Bone Metastasis Companies

Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc., BiologicsMD, Luye Pharma Group Ltd., QSAM Biosciences Inc., Serene, LLC, Isotopen Technologien Munchens and others.

Bone Metastases Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Bone Metastasis Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Transform your understanding of the Bone Metastasis Pipeline! See the latest progress in drug development and clinical research @ Bone Metastasis Market Drivers and Barriers, and Future Perspectives

Scope of the Bone Metastasis Pipeline Report

• Coverage- Global
• Bone Metastasis Companies- Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc., BiologicsMD, Luye Pharma Group Ltd., QSAM Biosciences Inc., Serene, LLC, Isotopen Technologien Munchens and others.
• Bone Metastasis Pipeline Therapies- Radium Ra 223 Dichloride, MW032, Xgeva, Zoledronic Acid, Radium-223 chloride (BAY88-8223), Pamidronate, Docetaxel and others.
• Bone Metastasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Bone Metastasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Research-Access the Full Bone Metastasis Pipeline Analysis Today! @ Bone Metastasis Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Bone Metastases: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Bone Metastases – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. MW032: Mabwell (Shanghai) Bioscience Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cabozantinib: Exelixis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ALMB-0168: AlaMab Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. BMD 3151: BiologicsMD
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Bone Metastases Key Companies
21. Bone Metastases Key Products
22. Bone Metastases- Unmet Needs
23. Bone Metastases- Market Drivers and Barriers
24. Bone Metastases- Future Perspectives and Conclusion
25. Bone Metastases Analyst Views
26. Bone Metastases Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-metastasis-pipeline-insight